American Diabetes Association 83rd Scientific Sessions (ADA 2023)
San Diego, California, US 23 June 2023 - 26 June 2023
Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run
Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.
Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run
21 Jul 2023
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
18 Jul 2023
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
17 Jul 2023
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).